Affordable Access

Publisher Website

Causal prophylactic efficacy of atovaquone-proguanil (MalaroneTM) in a human challenge model

Authors
Journal
Transactions of the Royal Society of Tropical Medicine and Hygiene
0035-9203
Publisher
Oxford University Press
Publication Date
Volume
95
Issue
4
Identifiers
DOI: 10.1016/s0035-9203(01)90206-8
Keywords
  • Chemotherapy And Chemoprophylaxis

Abstract

Abstract Plasmodia infect the liver for about 7 days before subsequently infecting the blood. Present prophylaxis against Plasmodium falciparum malaria employs agents that primarily kill blood stages and must be continued for 28 days after the last exposure. Atovaquone-proguanil (Malarone TM) is a new antimalarial agent that is licensed in 35 countries as treatment against blood-stage infection, but its components (atovaquone and proguanil) have separately been shown to be active also against liver stages. To determine whether atovaquone-proguanil is sufficiently active against liver stages to be discontinued 7 days after exposure, we challenged 16 volunteers with P. falciparum via infected mosquitoes. Twelve volunteers received atovaquone-proguanil (1 tablet daily) on the day prior to challenge, on the day of challenge, and for the next 6 days; 4 volunteers received matching placebo. All placebo volunteers demonstrated parasitaemia and malarial symptoms beginning on days 11–12 after challenge. No atovaquone-proguanil volunteer acquired malaria. Atovaquone-proguanil is the first licensed antimalarial agent that kills P. falciparum in the liver and that may be discontinued 7 days after the last exposure.

There are no comments yet on this publication. Be the first to share your thoughts.